Variant Hemoglobin Control, AE

Hemoglobin E is a fairly rare hemoglobinopathy in the United States. However, it occurs in the 30– 50 million person range in Asia, mainly among southeast Asian peoples. Therefore, a high incidence of hemoglobin E is to be expected among such populations both in America and in Europe. Because of the overlap between hemoglobin E and beta thalassemia, there may be severe clinical symptoms amongst heterozygous E patients due to the combined hemoglobinopathies (E & beta thalassemia). Due to the electrophoresis mobility properties, structural stability and other physical characteristics of these hemoglobins, good technique and appropriate controls are essential in the correct identification of these hemoglobinopathies. Care also should be taken to properly identify and quantitate hemoglobin A2 when thalassemia is suspected. BGT makes a heterozygous quality control sample. The donor AE has been carefully tested and properly identified to assure analysts that a proper E hemoglobin in present.

• HB-117 6X0.5 ml (DIMDI Reg.-Nr.: DE/CA22/1116-225-IVD)

Manufacturer:

Von-Langen-Weg 10 D-48565 Steinfurt Tel.: 02551/4090  Fax.: 02551/1298 Web: www.biogentechnologies.com